New Alzheimer's drug OLX-07010 enters first human safety trial
NCT ID NCT05696483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study tests the safety of OLX-07010, a drug designed to stop tau proteins from clumping in the brain—a hallmark of Alzheimer's disease. Researchers will give single or multiple doses to 88 healthy adults and elderly volunteers to see how the body handles the drug and if it causes side effects. This is the first time OLX-07010 is being tested in humans, so the main goal is safety, not effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OLX-07010 (a tau self-association inhibitor)
What this could lead to
If successful, this early study could pave the way for a treatment that slows Alzheimer's by preventing tau protein clumps in the brain.
What could go wrong
This is a very early Phase 1 safety trial in healthy people, not patients. It is too soon to know if OLX-07010 will work for Alzheimer's, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Clinical Trials Medical Group, Inc
Glendale, California, 91206, United States